Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.

Abstract

BACKGROUND:

The third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can penetrate blood-brain barrier and are effective for brain metastases (BMs). There is no consensus on the optimal sequence of local therapy (LT) and EGFR-TKIs for symptomatic BM patients because patients suffering neurological symptoms were not enrolled in most clinical trials.

METHODS:

Non-small cell lung cancer (NSCLC) patients with EGFR mutation (EGFRm) and symptomatic BM receiving first-line osimertinib and aumolertinib from two medical centers were collected. All participants were allocated into the third-generation EGFR-TKIs (TKIs) group and the upfront LT (uLT) plus third-generation EGFR-TKIs (TKIs + uLT) group. Demographic data, survival outcomes, treatment failure patterns, and adverse events were evaluated between the two groups. We also conducted subgroup analyses to explore the impact of BM number on survival outcomes.

RESULTS:

86 patients were enrolled, 44 in the TKIs group and 42 in the TKIs + uLT group. There were no significant differences in the short-term response between the groups. TKIs + uLT was associated with significantly longer overall survival (OS) (43 vs. 28 months; hazard ratio [HR], 0.36, 95% confidence interval [CI], 0.17-0.77; p = .011). No differences in progression-free survival (PFS), intracranial PFS (iPFS), failure patterns, or safety were observed. In subgroup analyses of oligo-BM patients, TKIs + uLT could prolong OS (43 vs. 31 months; HR 0.22; 95% CI 0.05-0.92; p = .015).

CONCLUSIONS:

EGFRm NSCLC patients with symptomatic BM might benefit from uLT, particularly oligo-BM patients. However, larger prospective cohort studies should be carried out to confirm the responses of the TKIs + uLT scheme.

• Authors: Lishui Niu, Honghua Wu, Ruihuan Gao, Liu Chen, Jiangtao Wang, Hexin Duan, Yujiao Long, Yi Xie, Qin Zhou, Rongrong Zhou
• Journal: Journal of cancer research and clinical oncology (J Cancer Res Clin Oncol) Vol. 150 Issue 2 Pg. 94 (Feb 19 2024) ISSN: 1432-1335 [Electronic] Germany
• PMID: 38369644 (Publication Type: Journal Article)
• Copyright: © 2024. The Author(s).

Chemical References

• EGFR protein, human
• ErbB Receptors
• Tyrosine Kinase Inhibitors

Topics

• Humans
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, pathology)
• ErbB Receptors (genetics)
• Lung Neoplasms (drug therapy, genetics, pathology)
• Mutation
• Prospective Studies
• Retrospective Studies
• Tyrosine Kinase Inhibitors (therapeutic use)